DOCSLIB.ORG

Differential Antagonism of the Rate-Decreasing Effects of Κ-Opioid

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Differential Antagonism of the Rate-Decreasing Effects of Κ-Opioid European Journal of Pharmacology 377Ž. 1999 21±28 www.elsevier.nlrlocaterejphar Differential antagonism of the rate-decreasing effects of k-opioid receptor agonists by naltrexone and norbinaltorphimine 1 Kelly R. Powell ), Stephen G. Holtzman Department of Pharmacology, Emory UniÕersity School of Medicine, 1510 Clifton Road, Atlanta, GA 30322, USA Received 28 January 1999; received in revised form 17 May 1999; accepted 26 May 1999 Abstract Eight k-opioid receptor agonists were examined for their effects in squirrel monkeys responding under a fixed interval 3-min schedule of stimulus termination. Six of these k-opioid receptor agonists decreased dose-dependently the total number of responses and with an order of potency consistent with k-opioid receptor interaction. Three of these k-opioid receptor agonists, bremazocine, U69,593 ÄwŽ.Ž.5a,7a,8b - q -N-w 7-Ž.Ž.. 1-pyrrolidinyl -1-oxaspiro 4,5 dec-8-ylx benzeneacetamide4 and enadoline, were evaluated following pretreat- ment with 1.0 mgrkg of naltrexone or 3.0 mgrkg of norbinaltorphimine. The effects of the three agonists were antagonized significantly by naltrexone, but only those of bremazocine and U69,593 were antagonized significantly by norbinaltorphimine. Statistical analysis of the data averaged over six monkeys revealed that naltrexone was significantly more potent than norbinaltorphimine at antagonizing enadoline and U69,593, but naltrexone and norbinaltorphimine were equipotent at antagonizing bremazocine. Moreover, naltrexone was 8-fold more potent at antagonizing U69,593 and enadoline than at antagonizing bremazocine. These results suggest that under these conditions the effects of U69,593 and enadoline may be mediated, in part, by a different receptor population, perhaps a subtype of k-opioid receptors, from the one that mediates the effects of bremazocine. q 1999 Elsevier Science B.V. All rights reserved. Keywords: k-Opioid receptor;Ž. Squirrel monkey ; Fixed interval; Naltrexone; Nor-binaltorphimine X 1. Introduction 5r,9r.Ž-5,9-dimethyl-2- 1-tetrahydrofurfuryl-2 -hydro-6,7- benzomorphan.x4 , but not ethylketocyclazocine and tiflu- Since the discovery of drugs that act selectively at adom, increase plasma levels of dihydroxyphenylacetic k-opioid receptors scientists have attempted to distinguish acid and homovanillic acidŽ. Iyengar et al., 1986 . In the mechanisms of action underlying the analgesic and addition, whereas ethylketocyclazocine- and tifluadom-in- unwanted side effects of these drugs. The hypothesis driv- duced decreases in plasma levels of corticosterone and ing this line of investigation is that more selective k-opioid thyroid stimulating hormone are blocked with the opioid receptor agonists can be developed that provide clinically antagonist quadazocine, U50,488- and MR-2034-induced useful analgesic effects without the unwanted side effects decreases are not. Furthermore, there are at least two or abuse potential. To this end, functional differences studies in mice in which antinociceptive cross-tolerance between k-opioid receptor agonists have been examined in between k-opioid receptor agonists was not observed: various physiological and behavioral assays, suggesting the U69,593ÄwŽ.Ž. 5a,7a,8 b - q -N-w 7-Ž. 1-pyrrolidinyl -1- existence of subtypes of the k-opioid receptor. For exam- oxaspiroŽ. 4,5 dec-8-yl .x benzene-acetamide4 and brema- ple, the k-opioid receptor agonists U50,488 Äwtrans- zocineŽ. Horan and Porreca, 1993 , and U50,488 and nalox- Ž." 3,4-dichloro-N-methyl-N-w 2-Ž. 1-pyrrolidinyl cyclo- one benzoylhydrazoneŽ. Gistrak et al., 1989 . hexylx benzeneacetamide4Ä and MR-2034 wŽ.y -a-l Žr, Traditionally, receptor-selective antagonists have been used to differentiate among receptors mediating the in vivo effects of various types of opioids Ž.m vs. k vs. d . The ) Corresponding author. Tel.: q1-404-727-0356; fax: q1-404-727- lack of antagonists selective for proposed subtypes of the 0365; E-mail: [email protected] k-opioid receptor has been a major impediment to the 1 This research was supported in part by Grant DA 00541, individual post-doctoral fellowship F32 DA05709 to K.R.P., and Research Scientist differentiation and characterization of those receptors. Award K05 DA00008 to S.G.H., all from the National Institute on Drug Nonetheless, important behavioral distinctions among k- Abuse, NIH. opioid receptor agonists have been demonstrated using the 0014-2999r99r$ - see front matter q 1999 Elsevier Science B.V. All rights reserved. PII: S0014-2999Ž. 99 00394-5 22 K.R. Powell, S.G. HoltzmanrEuropean Journal of Pharmacology 377() 1999 21±28 non-selective opioid antagonistsŽ antagonists that are capa- lidinyl. -cyclohexylxwx benzo b thiophene-4-acetamide xŽ Clark ble of antagonizing m- andror d- andror k-opioid recep- et al., 1989.Ž , spiradoline VonVoigtlander and Lewis, tor agonists. that are currently available. For example, in 1988.Ž , U50,488 VonVoigtlander et al., 1983 . , and U69,593 mice the antinociceptive effects of U69,593 are antago- Ž.Lahti et al., 1985 , represent two chemical families and a nized by the reported selectiveŽ. De Costa et al., 1989 range of relative affinities for k-opioid receptorsŽ see Nock k-opioid receptor antagonist Ž.y -UPHITÄ 1S,2S-trans-2- et al., 1988a; France et al., 1994. In order to establish that isothiocyanato-4,5-dichloro-N-methyl-N-w 2-Ž. 1-pyrrolidinyl k-opioid receptors mediate the dependent measure in the cyclohexylx benzeneacetamide4 , but not by the non-selec- present study, the rank order of potencies for the kappa tiveŽ. Dykstra et al., 1987; Pitts and Dykstra, 1994 opioid agonists in this study were compared to the potency order receptor antagonist quadazocine, whereas the antinocicep- of the same drugs in different procedures. Similar rank tive effects of bremazocine are antagonized by quada- orders of potency across procedures is suggestive that the zocine, but not by Ž.y -UPHIT Ž Horan et al., 1991, 1993 . effects are mediated by the same population of receptors. In these same studies, the antinociceptive effects of wD-Pen2 , In addition, antagonism of the effects of these k-opioid D-Pen5 x enkephalin Ž.d-opioid receptor agonist and Tyr-D- receptor agonists by the selective k-opioid receptor antago- Ala-Gly-NMe-Gly-ol Ž.m-opioid receptor agonist are an- nist norbinaltorphimine should rule out non-k-opioid re- tagonized by quadazocine at doses 3-fold less than the ceptors as the site of action for these effects. Finally, we dose required to antagonize bremazocine. Additionally, in compared the ability of the non-selective opioid receptor pigeons, lower doses of the non-selective opioid antago- antagonist naltrexone to antagonize the effects of three of nists naltrexone and naloxone are required to antagonize the k-opioid receptor agonists. If these k-opioid receptor the rate-decreasing and discriminative stimulus effects of agonists produce their effects through a homogenous re- bremazocine and enadoline than are required to antagonize ceptor population, the potency of a given antagonist should these effects of U50,488Ž Mattox et al., 1994; Picker, not differ across agonists. 1994. Furthermore, naltrexone differs in its ability to antagonize the rate-decreasing effects of bremazocine com- pared to U50,488 in ratsŽ. Pitts et al., 1996 . The selective 2. Materials and methods k-opioid receptor antagonist norbinaltorphimine Ž.Portoghese et al., 1987 antagonizes the antinociceptive 2.1. Subjects effects of U69,593 and U50,488, but not those of brema- zocine, enadoline, and ethylketocyclazocine in rhesus Ž. monkeysŽ. Butelman et al., 1993 . Similarly, the non-selec- Six squirrel monkeys Saimiri sciureus with previous tive opioid antagonist naltrexone is much more potent at experience on a fixed interval stimulus termination sched- antagonizing the antinociceptive effects of U50,488 and ule and previous exposure to various opioid drugs were U69,593 than at antagonizing the effects of bremazocine used in the present study. All monkeys were drug-free for and enadoline in rhesus monkeysŽ. Ko et al., 1998 . To- at least 1 year prior to this experiment. Monkeys were gether, these reports suggest that non-selective antagonists given food and water ad libitum in the home cages and might be useful in differentiating behavioral effects medi- received fresh fruit, peanuts, or a nutritional supplement ated by different receptor subtypes. daily. The facility for housing the animals was accredited Along this line, some investigators have suggested that by the American Association for Accreditation of Labora- the differences in the pharmacological profiles of these tory Animal Care and care of the animals conformed to the antagonists against different k-opioid receptor agonists National Institutes of Health Guide for the Care and Use of represent activity at different subtypes of the k-opioid Laboratory Animals. receptorŽ. Horan et al., 1993; Ko et al., 1998 . Based on that assumption and in order to provide further evidence 2.2. Apparatus for k-opioid receptor subtypes, the purpose of the current study was to compare the antagonism by naltrexone and The monkeys were restrained in a small primate chair norbinaltorphimine of the effects of various k-opioid re- that was placed inside a ventilated, sound-attenuating ceptor agonists in squirrel monkeys responding under a chamber provided with white noise during the experimen- fixed interval schedule of stimulusrshock termination. This tal sessions. The chamber was illuminated by a house light stimulus termination procedure was chosen based on our that was mounted on the rear wall of the chamber. A observations that it is sensitive to the k-opioid receptor- shaved portion of the monkey's tail was secured beneath mediated rate-decreasing effects of k-opioid receptor ago- two brass electrodes and held in place by a Plexiglas stock; nistsŽ. Jones and Holtzman, 1994 . The k-opioid receptor the electrodes were connected to a current generatorŽ Med agonists that were examined, bremazocineŽ Romer et al., Associates, Fairfield, VT. One response lever was mounted 1980.Ž , enadoline Boyle et al., 1990 .
Load more

Recommended publications
  • Addictions and the Brain
    9/18/2012 Addictions and the Brain TAAP Conference September 14, 2012 Acknowledgements • La Hacienda Treatment Center • American Society of Addiction Medicine • National Institute of Drug Abuse © 2012 La Hacienda Treatment Center. All rights reserved. 1 9/18/2012 Definition • A primary, progressive biochemical, psychosocial, genetically transmitted chronic disease of relapse who’s hallmarks are denial, loss of control and unmanageability. DSM IV Criteria for dependency: At least 3 of the 7 below 1. Withdrawal 2. Tolerance 3. The substance is taken in larger amounts or over a longer period than was intended. 4. There is a persistent desire or unsuccessful efforts to cut down or control substance use. 5. A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from its effects. 6. Important social, occupational, or recreational activities are given up or reduced because of the substance use. 7. The substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance. © 2012 La Hacienda Treatment Center. All rights reserved. 2 9/18/2012 Dispute between behavior and disease Present understanding of the Hypothalamus location of the disease hypothesis. © 2012 La Hacienda Treatment Center. All rights reserved. 3 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 4 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 5 9/18/2012 Dispute regarding behavior versus disease © 2012 La Hacienda Treatment Center. All rights reserved. 6 9/18/2012 © 2012 La Hacienda Treatment Center.
    [Show full text]
  • Euphoric Non-Fentanil Novel Synthetic Opioids on the Illicit Drugs Market
    Forensic Toxicology (2019) 37:1–16 https://doi.org/10.1007/s11419-018-0454-5 REVIEW ARTICLE The search for the “next” euphoric non‑fentanil novel synthetic opioids on the illicit drugs market: current status and horizon scanning Kirti Kumari Sharma1,2 · Tim G. Hales3 · Vaidya Jayathirtha Rao1,2 · Niamh NicDaeid4,5 · Craig McKenzie4 Received: 7 August 2018 / Accepted: 11 November 2018 / Published online: 28 November 2018 © The Author(s) 2018 Abstract Purpose A detailed review on the chemistry and pharmacology of non-fentanil novel synthetic opioid receptor agonists, particularly N-substituted benzamides and acetamides (known colloquially as U-drugs) and 4-aminocyclohexanols, developed at the Upjohn Company in the 1970s and 1980s is presented. Method Peer-reviewed literature, patents, professional literature, data from international early warning systems and drug user fora discussion threads have been used to track their emergence as substances of abuse. Results In terms of impact on drug markets, prevalence and harm, the most signifcant compound of this class to date has been U-47700 (trans-3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide), reported by users to give short- lasting euphoric efects and a desire to re-dose. Since U-47700 was internationally controlled in 2017, a range of related compounds with similar chemical structures, adapted from the original patented compounds, have appeared on the illicit drugs market. Interest in a structurally unrelated opioid developed by the Upjohn Company and now known as BDPC/bromadol appears to be increasing and should be closely monitored. Conclusions International early warning systems are an essential part of tracking emerging psychoactive substances and allow responsive action to be taken to facilitate the gathering of relevant data for detailed risk assessments.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20100227876A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0227876 A1 Rech (43) Pub. Date: Sep. 9, 2010 (54) METHODS OF REDUCING SIDE EFFECTS Publication Classi?cation OF ANALGESICS (51) Int CL A61K 31/485 (2006.01) A61K 31/40 (2006.01) (75) Inventor: Richard H. Rech, Okemos, MI A61K 31/445 (2006-01) (Us) A61K 31/439 (2006.01) (52) US. Cl. ........................ .. 514/282; 514/409; 514/329 (57) ABSTRACT Correspondence Address: The invention provides for compositions and methods of MARSHALL, GERSTEIN & BORUN LLP reducing pain in a subject by administering a combination of 233 SOUTH WACKER DRIVE, 6300 WILLIS mu-opioid receptor agonist, kappal-opioid receptor agonist TOWER and a nonselective opioid receptor antagonist in amounts CHICAGO, IL 60606-6357 (US) effective to reduce pain and ameliorate an adverse side effect of treatment combining opioid-receptor agonists. The inven tion also provides for methods of enhancing an analgesic effect of treatment With an opioid-receptor agonist in a sub (73) Assignee: RECHFENSEN LLP, RidgeWood, ject suffering from pain While reducing an adverse side effect NJ (US) of the treatment. The invention also provides for methods of reducing the hyperalgesic effect of treatment With an opioid receptor agonist in a subject suffering from pain While reduc ing an adverse side effect of the treatment. The invention (21) Appl. No.: 12/399,629 further provides for methods of promoting the additive anal gesia of pain treatment With an opioid-receptor agonist in a subject in need While reducing an adverse side effect of the (22) Filed: Mar.
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • Opioids and Nicotine Dependence in Planarians
    Pharmacology, Biochemistry and Behavior 112 (2013) 9–14 Contents lists available at ScienceDirect Pharmacology, Biochemistry and Behavior journal homepage: www.elsevier.com/locate/pharmbiochembeh Opioid receptor types involved in the development of nicotine physical dependence in an invertebrate (Planaria)model Robert B. Raffa a,⁎, Steve Baron a,b, Jaspreet S. Bhandal a,b, Tevin Brown a,b,KevinSongb, Christopher S. Tallarida a,b, Scott M. Rawls b a Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA, USA b Department of Pharmacology & Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA, USA article info abstract Article history: Recent data suggest that opioid receptors are involved in the development of nicotine physical dependence Received 18 May 2013 in mammals. Evidence in support of a similar involvement in an invertebrate (Planaria) is presented using Received in revised form 18 September 2013 the selective opioid receptor antagonist naloxone, and the more receptor subtype-selective antagonists CTAP Accepted 21 September 2013 (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH )(μ, MOR), naltrindole (δ, DOR), and nor-BNI (norbinaltorphimine) Available online 29 September 2013 2 (κ, KOR). Induction of physical dependence was achieved by 60-min pre-exposure of planarians to nicotine and was quantified by abstinence-induced withdrawal (reduction in spontaneous locomotor activity). Known MOR Keywords: Nicotine and DOR subtype-selective opioid receptor antagonists attenuated the withdrawal, as did the non-selective Abstinence antagonist naloxone, but a KOR subtype-selective antagonist did not. An involvement of MOR and DOR, but Withdrawal not KOR, in the development of nicotine physical dependence or in abstinence-induced withdrawal was thus Physical dependence demonstrated in a sensitive and facile invertebrate model.
    [Show full text]
  • Table of Contents
    TheJournalof VOLUME271 PHARMACOLOGY NUMBER 3 AND EXPERIMENTAL THERAPEUTICS Contents ANTI-INFLAMMATORIES Lecithinized Superoxide Dismutase Enhances Its R. Igarashi, J. Hoshino, A. Ochiai, 1672 Pharmacologic Potency by Increasing Its Cell Membrane Y. Morizawa and Y. Mizushima Affinity ANALGESICS Role of Endogenous Cholecystokinin in the Facilitation of Mu- Florence Noble, Claire Smadja and 1127 Mediated Antinociception by Delta.Opioid Agonists Bernard P. Roques Downloaded from GBR12909 Attenuates Cocaine-Induced Activation of Michael H. Baumann, George U. Char, 1216 Mesolimbic Dopamine Neurons in the Rat Brian R. Dc Costa, Kenner C. Rice and Richard B. Rothman Substance P N-Terminal Metabolites and Nitric Oxide Mediate Julie S. Kreeger, Kelley F. Kitto and 1281 Capsaicin-Induced Antinociception in the Adult Mouse Alice A. Larson Antinociceptive Actions of Dexmedetomidine and the Kappa- Juhana J. Idanpaan-Heikkila, Eija A. Kalso 1306 jpet.aspetjournals.org Opioid Agonist U.5O,488H against Noxious Thermal, and Timo Seppala Mechanical and Inflammatory Stimuli Involvement of NMDA Receptors in Naloxone-Induced Rustam Yu. Yukhananov and 1365 Contractions of the Isolated Guinea Pig ileum after Alice A. Larson Preincubation with Morphine Development of Cross-Tolerance between - Fang Fan, David R. Compton, Susan Ward, 1383 Tetrahydrocannabinol, CP 55,940 and WIN 55,212 Lawrence Melvin and Billy R. Martin at ASPET Journals on October 2, 2021 Antinociceptive and Response Rate-Altering Effects of Kappa Raymond C. Pitts and Linda A. Dykstra 1501 Opioid Agonists, Spiradoline, Enadoline and U69,593, Alone and in Combination with Opioid Antagonists in Squirrel Monkeys The Influence of Pharmacogenetics on Opioid Analgesia: Jim Cleary, Gerd Mikus, Andrew Somogyi 1528 Studies with Codeine and Oxycodone in the Sprague-Dawley/ and Felix Bochner Dark Agouti Rat Model Selective Antagonism of Opioid Analgesia by a Sigma System Chih-Cheng Chien and 1583 Gavril W.
    [Show full text]
  • Measures and CDS for Safer Opioid Prescribing: a Literature Review
    Measures and CDS for Safer Opioid Prescribing: A Literature Review Measures and CDS for Safer Opioid Prescribing: A Literature Review Executive Summary The U.S. opioid epidemic continues to pose significant challenges for patients, families, clinicians, and public health policy. Opioids are responsible for an estimated 315,000 deaths (from 1999 to 2016) and have caused 115 deaths per day.1 In 2017, the U.S. Department of Health and Human Services declared the opioid epidemic a public health crisis.2 The total economic burden of opioid abuse in the United States has been estimated to be $78.5 billion per year.3 Although providing care for chronic opioid users is important, equally vital are efforts to prevent so-called opioid-naïve patients (patients with no history of opioid use) from developing regular opioid use, misuse, or abuse. However, much remains unclear regarding what role clinician prescribing habits play and what duration or dose of opioids may safely be prescribed without promoting long-term use.4,5 In 2013, ECRI Institute convened the Partnership for Health IT Patient Safety, and its component, single-topic-focused workgroups followed. For this subject, the Electronic Health Record Association (EHRA): Measures and Clinical Decision Support (CDS) for Safer Opioid Prescribing workgroup included members from the Healthcare Information and Management Systems Society (HIMSS) EHRA and the Partnership team. The project was oriented towards exploring methods to enable a synergistic cycle of performance measurement and identifying electronic health record (EHR)/health information technology (IT)–enabled approaches to support healthcare organizations’ ability to assess and measure opioid prescribing.
    [Show full text]
  • BBC Program 2016.Pages
    March 5-6, 2016 La Quinta Inn & Suites Medical Center San Antonio, TX Behavior, Biology, and Chemistry: Translational Research in Addiction BBC 2016 BBC Publications BBC 2011 Stockton Jr SD and Devi LA (2012) Functional relevance of μ–δ opioid receptor heteromerization: A Role in novel signaling and implications for the treatment of addiction disorders: From a symposium on new concepts in mu-opioid pharmacology. Drug and Alcohol Dependence Mar 1;121(3):167-72. doi: 10.1016/j.drugalcdep.2011.10.025. Epub 2011 Nov 23 Traynor J (2012) μ-Opioid receptors and regulators of G protein signaling (RGS) proteins: From a sym- posium on new concepts in mu-opioid pharmacology. Drug and Alcohol Dependence Mar 1;121(3): 173-80. doi: 10.1016/j.drugalcdep.2011.10.027. Epub 2011 Nov 29 Lamb K, Tidgewell K, Simpson DS, Bohn LM and Prisinzano TE (2012) Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: New concepts in mu opioid receptor pharmacology: From a symposium on new concepts in mu-opioid pharma- cology. Drug and Alcohol Dependence Mar 1;121(3):181-8. doi: 10.1016/j.drugalcdep.2011.10.026. Epub 2011 Nov 26 Whistler JL (2012) Examining the role of mu opioid receptor endocytosis in the beneficial and side-ef- fects of prolonged opioid use: From a symposium on new concepts in mu-opioid pharmacology. Drug and Alcohol Dependence Mar 1;121(3):189-204. doi: 10.1016/j.drugalcdep.2011.10.031. Epub 2012 Jan 9 BBC 2012 Zorrilla EP, Heilig M, de Wit, H and Shaham Y (2013) Behavioral, biological, and chemical perspectives on targeting CRF1 receptor antagonists to treat alcoholism.
    [Show full text]
  • 212102Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 212102Orig1s000 OTHER REVIEW(S) Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research | Office of Surveillance and Epidemiology (OSE) Epidemiology: ARIA Sufficiency Date: June 29, 2020 Reviewer: Silvia Perez-Vilar, PharmD, PhD Division of Epidemiology I Team Leader: Kira Leishear, PhD, MS Division of Epidemiology I Division Director: CAPT Sukhminder K. Sandhu, PhD, MPH, MS Division of Epidemiology I Subject: ARIA Sufficiency Memo for Fenfluramine-associated Valvular Heart Disease and Pulmonary Arterial Hypertension Drug Name(s): FINTEPLA (Fenfluramine hydrochloride, ZX008) Application Type/Number: NDA 212102 Submission Number: 212102/01 Applicant/sponsor: Zogenix, Inc. OSE RCM #: 2020-953 The original ARIA memo was dated June 23, 2020. This version, dated June 29, 2020, was amended to include “Assess a known serious risk” as FDAAA purpose (per Section 505(o)(3)(B)) to make it consistent with the approved labeling. The PMR development template refers to the original memo, dated June 23, 2020. Page 1 of 13 Reference ID: 46331494640015 EXECUTIVE SUMMARY (place “X” in appropriate boxes) Memo type -Initial -Interim -Final X X Source of safety concern -Peri-approval X X -Post-approval Is ARIA sufficient to help characterize the safety concern? Safety outcome Valvular Pulmonary heart arterial disease hypertension (VHD) (PAH) -Yes -No X X If “No”, please identify the area(s) of concern. -Surveillance or Study Population X X -Exposure -Outcome(s) of Interest X X -Covariate(s) of Interest X X -Surveillance Design/Analytic Tools Page 2 of 13 Reference ID: 46331494640015 1.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0245287 A1 Holaday Et Al
    US 20110245287A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0245287 A1 Holaday et al. (43) Pub. Date: Oct. 6, 2011 (54) HYBRD OPOD COMPOUNDS AND Publication Classification COMPOSITIONS (51) Int. Cl. A6II 3/4748 (2006.01) C07D 489/02 (2006.01) (76) Inventors: John W. Holaday, Bethesda, MD A6IP 25/04 (2006.01) (US); Philip Magistro, Randolph, (52) U.S. Cl. ........................................... 514/282:546/45 NJ (US) (57) ABSTRACT Disclosed are hybrid opioid compounds, mixed opioid salts, (21) Appl. No.: 13/024,298 compositions comprising the hybrid opioid compounds and mixed opioid salts, and methods of use thereof. More particu larly, in one aspect the hybrid opioid compound includes at (22) Filed: Feb. 9, 2011 least two opioid compounds that are covalently bonded to a linker moiety. In another aspect, the hybrid opioid compound relates to mixed opioid salts comprising at least two different Related U.S. Application Data opioid compounds or an opioid compound and a different active agent. Also disclosed are pharmaceutical composi (60) Provisional application No. 61/302,657, filed on Feb. tions, as well as to methods of treating pain in humans using 9, 2010. the hybrid compounds and mixed opioid salts. Patent Application Publication Oct. 6, 2011 Sheet 1 of 3 US 2011/0245287 A1 Oral antinociception of morphine, oxycodone and prodrug combinations in CD1 mice s Tigkg -- Morphine (2.80 mg/kg (1.95 - 4.02, 30' peak time -- (Oxycodone (1.93 mg/kg (1.33 - 2,65)) 30 peak time -- Oxy. Mor (1:1) (4.84 mg/kg (3.60 - 8.50) 60 peak tire --MLN 2-3 peak, effect at a hors 24% with closes at 2.5 art to rigg - D - MLN 2-45 (6.60 mg/kg (5.12 - 8.51)} 60 peak time Figure 1.
    [Show full text]
  • Kappa Opioid Regulation of Depressive-Like Behavior During Acute Withdrawal and Protracted Abstinence from Ethanol Sorscha K
    Grand Valley State University ScholarWorks@GVSU Funded Articles Open Access Publishing Support Fund 9-2018 Kappa Opioid Regulation of Depressive-Like Behavior During Acute Withdrawal and Protracted Abstinence from Ethanol Sorscha K. Jarman Grand Valley State University, [email protected] Alison M. Haney Grand Valley State University, [email protected] Glenn R. Valdez Grand Valley State University, [email protected] Follow this and additional works at: https://scholarworks.gvsu.edu/oapsf_articles Part of the Chemicals and Drugs Commons ScholarWorks Citation Jarman, Sorscha K.; Haney, Alison M.; and Valdez, Glenn R., "Kappa Opioid Regulation of Depressive-Like Behavior During Acute Withdrawal and Protracted Abstinence from Ethanol" (2018). Funded Articles. 106. https://scholarworks.gvsu.edu/oapsf_articles/106 This Article is brought to you for free and open access by the Open Access Publishing Support Fund at ScholarWorks@GVSU. It has been accepted for inclusion in Funded Articles by an authorized administrator of ScholarWorks@GVSU. For more information, please contact [email protected]. RESEARCH ARTICLE Kappa opioid regulation of depressive-like behavior during acute withdrawal and protracted abstinence from ethanol ¤ Sorscha K. Jarman, Alison M. Haney , Glenn R. ValdezID* Department of Psychology, Grand Valley State University, Allendale, MI, United States of America ¤ Current address: Department of Psychology, Purdue University, West Lafayette, IN, United States of America * [email protected] a1111111111 a1111111111 a1111111111 a1111111111 Abstract a1111111111 The dynorphin/kappa opioid receptor (DYN/KOR) system appears to be a key mediator of the behavioral effects of chronic exposure to alcohol. Although KOR opioid receptor antago- nists have been shown to decrease stress-related behaviors in animal models during acute ethanol withdrawal, the role of the DYN/KOR system in regulating long-term behavioral OPEN ACCESS changes following protracted abstinence from ethanol is not well understood.
    [Show full text]
  • Datasheet Inhibitors / Agonists / Screening Libraries a DRUG SCREENING EXPERT
    Datasheet Inhibitors / Agonists / Screening Libraries A DRUG SCREENING EXPERT Product Name : Norbinaltorphimine dihydrochloride Catalog Number : T12241 CAS Number : 113158-34-2 Molecular Formula : C40H45Cl2N3O6 Molecular Weight : 734.71 Description: Norbinaltorphimine dihydrochloride is a potent and selective antagonist of κ opioid receptor. Storage: 2 years -80°C in solvent; 3 years -20°C powder; Receptor (IC50) κ opioid receptor In vivo Activity The KOR antagonist, Norbinaltorphimine(norBNI), had weak and inconsistent effects on THC-induced taste avoidance in adolescent rats in that norBNI both attenuated and strengthened taste avoidance dependent on dose and trial. norBNI had limited impact on the final one-bottle avoidance and no effects on the two-bottle preference test. Interestingly, norBNI had no effect on THC-induced taste avoidance in adult rats as well. Reference 1. Flax SM, et al. Effect of norbinaltorphimine on ∆⁹-tetrahydrocannabinol (THC)-induced taste avoidance in adolescent and adult Sprague-Dawley rats. Psychopharmacology (Berl). 2015 Sep;232(17):3193-201. 2. Jackson KJ, et al. Effects of the kappa opioid receptor antagonist, norbinaltorphimine, on stress and drug-induced reinstatement of nicotine-conditioned place preference in mice. Psychopharmacology (Berl). 2013 Apr;226(4):763-8. FOR RESEARCH PURPOSES ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE. Information for product storage and handling is indicated on the product datasheet. Targetmol products are stable for long term under the recommended storage conditions. Our products may be shipped under different conditions as many of them are stable in the short-term at higher or even room temperatures. We ensure that the product is shipped under conditions that will maintain the quality of the reagents.
    [Show full text]